STOCK TITAN

Moleculin Biotech, Inc. (MBRX) Net Income by Year

MBRX

Moleculin Biotech, Inc. reported $33.6M in net income in fiscal year 2025. This represents an increase of 28.8% from the prior fiscal year. The table below carries 11 fiscal years, from 2015 to 2025, and the quarters Moleculin Biotech, Inc. has filed alongside them.

FY2025 annual
Net Income $33.6M
YoY +28.8%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

MBRX Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-K
Net Income$33.6M+28.8%$26.0M-12.5%$29.8M+202.6%-$29.0M-82.6%-$15.9M+8.4%-$17.4M-31.4%-$13.2M-11.2%-$11.9M-21.1%-$9.8M-149.7%-$3.9MN/A

MBRX Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Net Income-$7.6M+57.1%-$12.8M-117.6%N/A-$25.4M-261.6%-$17.8M-196.1%-$5.9M+8.1%N/A-$7.0M-25.2%-$6.0M-0.7%-$6.4M+18.8%N/A-$5.6M+34.9%

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Moleculin Biotech, Inc. financials

Frequently Asked Questions

What was Moleculin Biotech, Inc.'s net income in fiscal year 2025?

Moleculin Biotech, Inc. reported $33.6M in net income in fiscal year 2025.

How fast is Moleculin Biotech, Inc.'s net income growing?

Moleculin Biotech, Inc. (MBRX) net income rose by 28.8% year over year, from $26.0M to $33.6M in fiscal year 2025.

What was Moleculin Biotech, Inc.'s net income in the most recent quarter?

Moleculin Biotech, Inc. (MBRX) reported -$7.6M in net income in Q2 2026. This represents an increase of 57.1% from the same quarter a year earlier.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Moleculin Biotech, Inc. (MBRX) reported on that line in every period on record.